Login to Your Account



Nanobiotix launches U.S. trial, enters hot immuno-oncology field

By John Brosky
Contributing Writer

Friday, January 8, 2016

PARIS – At the start of what promises to be a big year for nanomedicine developer Nanobiotix SA, of Paris, the company reported approval for its first clinical trial in the U.S. and a bold new program stepping into the fast-developing field of immuno-oncology.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription